Cargando…

Genomic Heterogeneity and Clonal Evolution in Gastroesophageal Junction Cancer Revealed by Single Cell DNA Sequencing

Gastroesophageal junction (GEJ) cancer is a tumor that occurs at the junction of stomach and esophagus anatomically. GEJ cancer frequently metastasizes to lymph nodes, however the heterogeneity and clonal evolution process are unclear. This study is the first of this kind to use single cell DNA sequ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duan, Qingke, Tang, Chao, Ma, Zhao, Chen, Chuangui, Shang, Xiaobin, Yue, Jie, Jiang, Hongjing, Gao, Yan, Xu, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144650/ https://www.ncbi.nlm.nih.gov/pubmed/34046362 http://dx.doi.org/10.3389/fonc.2021.672020

Ejemplares similares

Comparison of lymph node metastasis pattern from esophagogastric junction adenocarcinoma versus very low thoracic esophageal squamous cancer: a propensity-matched analysis
por: Ma, Zhao, et al.
Publicado: (2023)

Risk factors for lymph node metastasis of the left recurrent laryngeal nerve in patients with esophageal squamous cell carcinoma
por: Chen, Chuangui, et al.
Publicado: (2021)

Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers
por: Kastelowitz, Noah, et al.
Publicado: (2021)

Prognostic Nomogram for Postoperative Patients With Gastroesophageal Junction Cancer of No Distant Metastasis
por: Guo, Qiang, et al.
Publicado: (2021)

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)

Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab
por: Sama, Shashank, et al.
Publicado: (2019)

Lymph node ratio-based staging system as an alternative to the current TNM staging system to assess outcome in adenocarcinoma of the esophagogastric junction after surgical resection
por: Zhang, Hongdian, et al.
Publicado: (2016)

Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis
por: Walden, Daniel, et al.
Publicado: (2021)

Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis
por: Liu, Bo-Wei, et al.
Publicado: (2023)

Lymph node dissection around left recurrent laryngeal nerve: robot-assisted vs. video-assisted McKeown esophagectomy for esophageal squamous cell carcinoma
por: Duan, Xiaofeng, et al.
Publicado: (2020)

A nomogram to predict lymph node metastasis risk for early esophageal squamous cell carcinoma
por: Duan, Xiaofeng, et al.
Publicado: (2021)

Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?
por: Bai, Rilan, et al.
Publicado: (2020)

Fever of Undetermined Origin During Neoadjuvant Chemoradiotherapy of Gastroesophageal Junction Adenocarcinoma Due to Radiation-induced Liver Disease
por: Bashir, Babar, et al.
Publicado: (2019)

Characterization of genomic alterations and neoantigens and analysis of immune infiltration identified therapeutic and prognostic biomarkers in adenocarcinoma at the gastroesophageal junction
por: Lao, Yueqiong, et al.
Publicado: (2022)

Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002)
por: Shang, Xiaobin, et al.
Publicado: (2022)

The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma
por: van Hootegem, Sander J. M., et al.
Publicado: (2019)

Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
por: Anderegg, M. C. J., et al.
Publicado: (2017)

Genetic heterogeneity and clonal evolution in neuroblastoma
por: Mora, J, et al.
Publicado: (2001)

Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection
por: Shi, Jinming, et al.
Publicado: (2022)

Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer
por: Paschold, Lisa, et al.
Publicado: (2022)

Survival benefit after neoadjuvant or adjuvant radiotherapy for stage II–III gastroesophageal junction adenocarcinoma: A large population-based cohort study
por: Zuo, Zhichao, et al.
Publicado: (2022)

Dual-layer dual-energy CT for improving differential diagnosis of squamous cell carcinoma from adenocarcinoma at gastroesophageal junction
por: Wu, Meihong, et al.
Publicado: (2022)

Heterogeneity and evolution of tumour immune microenvironment in metastatic gastroesophageal adenocarcinoma
por: Wang, Wei, et al.
Publicado: (2022)

The Value of Paratracheal Lymphadenectomy in Esophagectomy for Adenocarcinoma of the Esophagus or Gastroesophageal Junction: A Systematic Review of the Literature
por: Gantxegi, Amaia, et al.
Publicado: (2021)

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis
por: Yuan, Zhen, et al.
Publicado: (2023)

Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
por: Bianchi, Giada, et al.
Publicado: (2014)

Intratumoral Heterogeneity and Clonal Evolution Induced by HPV Integration
por: Akagi, Keiko, et al.
Publicado: (2023)

Intratumoral heterogeneity and clonal evolution in liver cancer
por: Losic, Bojan, et al.
Publicado: (2020)

Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis
por: Kamarajah, Sivesh K., et al.
Publicado: (2021)

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
por: Wang, Jianzheng, et al.
Publicado: (2022)

Relevance of Position and Movement of the Gastroesophageal Junction in Gastroesophageal Reflux Disease
por: Lee, Yeong Yeh
Publicado: (2013)

Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective
por: Kwok, Marwan, et al.
Publicado: (2021)

The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma
por: Sandmann, Sarah, et al.
Publicado: (2022)

Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models
por: Kaehler, Meike, et al.
Publicado: (2023)

The Microbiome Tumor Axis: How the Microbiome Could Contribute to Clonal Heterogeneity and Disease Outcome in Pancreatic Cancer
por: Basu, Meghna, et al.
Publicado: (2021)

Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer
por: Sagawa, Tamotsu, et al.
Publicado: (2023)

Heterogenous profiles between primary lung cancers and paired brain metastases reveal tumor evolution
por: Chen, Yanming, et al.
Publicado: (2023)

Nanopore sequencing of clonal IGH rearrangements in cell-free DNA as a biomarker for acute lymphoblastic leukemia
por: Sampathi, Shilpa, et al.
Publicado: (2022)

Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China
por: Shu, Yamin, et al.
Publicado: (2022)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials
por: Zheng, Jianqing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4vidnks017a7g5epih5fct5en5